Jennifer Jaufmann, Marie-Therese Fleischmann, Fee Schmitt and Sandra Beer-Hammer*
Department of Pharmacology and Experimental Therapy, Eberhard Karls University Tübingen, GermanyFulltext PDF
Multiple Myeloma (MM) is a heterogeneous disease of the hematopoietic system that is characterized by the expansion of neoplastic plasma cells and is one of the most commonly diagnosed hematological tumors worldwide. Clinical manifestations of the malignancy involve renal impairment, anemia, hypercalcemia and bone destruction. Despite the fact that treatment strategies have drastically improved during the last few years, MM is still considered incurable. Several genetic abnormalities have been associated with the development of MM, including point mutations, translocations and aberrations of whole chromosomes. The inhibitory adaptor protein Src homology domain 3 lymphocyte protein 2 (SLy2) is located on chromosome 21q.11.2 and belongs into a group of genes frequently disrupted in MM patients. However, the role of SLy2 in intracellular plasma cell signaling and its involvement in MM development still remain unclear. In this study, we examine the expression profile of SLy2 in different human MM cell lines and discuss its possible contribution to Histone Deacetylase (HDAC)-mediated gene repression in MM.
HDAC; SLy2; Multiple myeloma; MGUS
Jaufmann J, Fleischmann M-T, Schmitt F, Beer-Hammer S. IL-6-Mediated Stimulation of RPMI 8226 Cells Induces Upregulation of the Inhibitory Adaptor SLy2 and Is Accompanied by Alterations in HDAC-Target Gene Expression. J Hematol Mult Myeloma. 2019;4(1):1019.